Pharming (PHAR) Group announced overnight that the National Institute for Health and Care Excellence has issued positive final guidance recommending Joenja for reimbursement and use within the National Health Service in England and Wales for the treatment of activated phosphoinositide 3-kinase delta syndrome in adult and pediatric patients 12 years of age and older. The company says Joenja is now available for use and funded in England through the Innovative Medicines Fund. In Wales, Joenja is expected to be funded within the next three months through the NHS in specialist centers.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PHAR:
- Pharming price target lowered to EUR 2 from EUR 2.15 at RBC Capital
- Pharming Group Files 2024 Annual Report and Form 20-F
- Pharming price target raised to $39 from $30 at Oppenheimer
- Pharming Group’s Strong Financial Performance and Strategic Initiatives Justify Buy Rating
- Pharming Group Reports Strong 2024 Revenue Growth